Compare · BIAF vs ICLR
BIAF vs ICLR
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and ICON plc (ICLR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and ICLR operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ICLR is the larger of the two at $12.93B, about 4206.6x BIAF ($3.1M).
- Over the past year, BIAF is down 95.5% and ICLR is down 2.4% - ICLR leads by 93.0 points.
- ICLR has been more active in the news (19 items in the past 4 weeks vs 12 for BIAF).
- ICLR has more recent analyst coverage (25 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- ICON plc
- Price
- $5.04-3.08%
- $167.69-0.79%
- Market cap
- $3.1M
- $12.93B
- 1M return
- -46.01%
- -6.94%
- 1Y return
- -95.47%
- -2.44%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1998
- News (4w)
- 12
- 19
- Recent ratings
- 0
- 25
ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
- bioAffinity Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- SEC Form 10-Q filed by bioAffinity Technologies Inc.
Latest ICLR
- SEC Form 6-K filed by ICON plc
- SEC Form 6-K filed by ICON plc
- Amendment: SEC Form SCHEDULE 13G/A filed by ICON plc
- Director O'Neill Julie converted options into 1,732 units of Ordinary Shares and sold $150,326 worth of Ordinary Shares (915 units at $164.29), increasing direct ownership by 30% to 3,515 units (SEC Form 4) to satisfy tax liability
- Director Whitaker Anne Clem converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29) (SEC Form 4) to satisfy tax liability
- Director Murray Ciaran sold $439,803 worth of Ordinary Shares (2,677 units at $164.29) and converted options into 2,677 units of Ordinary Shares (SEC Form 4) (for tax liability)
- Director Murphy Ronan Martin converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 30% to 3,847 units (SEC Form 4) (tax withholding)
- Director Mccague Eugene Pacelli converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 31% to 3,811 units (SEC Form 4) (tax liability)
- Director Grais Linda converted options into 1,732 units of Ordinary Shares and sold $138,169 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 17% to 6,162 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by Chief Accounting Officer Lyons Emer